Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Surface Oncology stock | 7.99

Own Surface Oncology stock in just a few minutes.

Posted

Fact checked

Surface Oncology, Inc is a biotechnology business based in the US. Surface Oncology shares (SURF) are listed on the NASDAQ and all prices are listed in US Dollars. Surface Oncology employs 49 staff and has a trailing 12-month revenue of around USD$39 million.

How to buy shares in Surface Oncology

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Surface Oncology. Find the stock by name or ticker symbol: SURF. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Surface Oncology reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$7.99, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Surface Oncology, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Surface Oncology. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Surface Oncology's share price?

Since the stock market crash in March caused by coronavirus, Surface Oncology's share price has had significant positive movement.

Its last market close was USD$7.99, which is 51.81% up on its pre-crash value of USD$3.85 and 478.99% up on the lowest point reached during the March crash when the shares fell as low as USD$1.38.

If you had bought USD$1,000 worth of Surface Oncology shares at the start of February 2020, those shares would have been worth USD$493.72 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$2,512.62.

Surface Oncology share price

Use our graph to track the performance of SURF stocks over time.

Surface Oncology shares at a glance

Information last updated 2020-11-17.
Latest market close USD$7.99
52-week range USD$1.38 - USD$10.25
50-day moving average USD$8.3943
200-day moving average USD$6.0966
Wall St. target price USD$13
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-1.327

Buy Surface Oncology shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Surface Oncology stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Surface Oncology price performance over time

Historical closes compared with the close of $7.99 from 2020-11-16

1 week (2020-11-13) -7.20%
1 month (2020-10-21) -10.12%
3 months (2020-08-21) 27.23%
6 months (2020-05-21) 34.29%
1 year (2019-11-21) 278.67%
2 years (2018-11-21) -4.77%
3 years (2017-11-20) N/A
5 years (2015-11-20) N/A

Surface Oncology financials

Revenue TTM USD$39 million
Gross profit TTM USD$-36,758,000
Return on assets TTM -9.48%
Return on equity TTM -30.91%
Profit margin -61.4%
Book value $2.119
Market capitalisation USD$325 million

TTM: trailing 12 months

Shorting Surface Oncology shares

There are currently 1.0 million Surface Oncology shares held short by investors – that's known as Surface Oncology's "short interest". This figure is 56.6% up from 656,489 last month.

There are a few different ways that this level of interest in shorting Surface Oncology shares can be evaluated.

Surface Oncology's "short interest ratio" (SIR)

Surface Oncology's "short interest ratio" (SIR) is the quantity of Surface Oncology shares currently shorted divided by the average quantity of Surface Oncology shares traded daily (recently around 1.3 million). Surface Oncology's SIR currently stands at 0.82. In other words for every 100,000 Surface Oncology shares traded daily on the market, roughly 820 shares are currently held short.

However Surface Oncology's short interest can also be evaluated against the total number of Surface Oncology shares, or, against the total number of tradable Surface Oncology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Surface Oncology's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Surface Oncology shares in existence, roughly 30 shares are currently held short) or 0.0354% of the tradable shares (for every 100,000 tradable Surface Oncology shares, roughly 35 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Surface Oncology.

Find out more about how you can short Surface Oncology stock.

Surface Oncology share dividends

We're not expecting Surface Oncology to pay a dividend over the next 12 months.

Surface Oncology share price volatility

Over the last 12 months, Surface Oncology's shares have ranged in value from as little as $1.38 up to $10.25. A popular way to gauge a stock's volatility is its "beta".

SURF.US volatility(beta: 2.27)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Surface Oncology's is 2.2715. This would suggest that Surface Oncology's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Surface Oncology overview

Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company develops human immunoglobulin isotype G4 monoclonal antibodies, including SRF231 inhibiting CD47; NZV930 inhibiting CD73; SRF617 inhibiting CD39; SRF388 targeting interleukin 27; and SRF813 targeting CD112R. It also develops various earlier stage programs that targets other critical components of the tumor microenvironment, including regulatory T cells and natural killer cells. The company has a strategic collaboration agreement with Novartis Institutes for Biomedical Research, Inc. for the development of cancer therapies; and the Merck Sharp & Dohme Corp. to evaluate the safety and efficacy of combining Surface's SRF617, an investigational antibody therapy targeting CD39, with Merck's KEYTRUDAÂ (pembrolizumab), the first anti-PD-1 therapy approved in the United States. Surface Oncology, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site